Jennifer Dine

ORCID: 0000-0002-2121-9752
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cell death mechanisms and regulation
  • Immunotherapy and Immune Responses
  • Lymphatic System and Diseases
  • Phagocytosis and Immune Regulation
  • Diet, Metabolism, and Disease
  • Cancer-related Molecular Pathways
  • Alcohol Consumption and Health Effects
  • PARP inhibition in cancer therapy
  • Liver Disease Diagnosis and Treatment
  • NF-κB Signaling Pathways
  • BRCA gene mutations in cancer
  • RNA Interference and Gene Delivery
  • Mental Health and Patient Involvement
  • Genetics and Neurodevelopmental Disorders
  • Cancer Immunotherapy and Biomarkers
  • Hormonal Regulation and Hypertension
  • Cancer survivorship and care
  • Physical Activity and Health
  • Lung Cancer Research Studies
  • Herbal Medicine Research Studies
  • Mitochondrial Function and Pathology
  • Obesity, Physical Activity, Diet
  • Cardiac Health and Mental Health
  • Dermatology and Skin Diseases
  • Immune Cell Function and Interaction

RTI Health Solutions
2020-2025

RTI International
2024

National Cancer Institute
2016-2022

National Institutes of Health
2012-2022

Center for Cancer Research
2014-2022

The Graduate Center, CUNY
2017

City University of New York
2017

National Institute of Nursing Research
2015

National Cancer Institute
2015

National Institute of Diabetes and Digestive and Kidney Diseases
2012

The COVID-19 Symptoms Daily Diary (CSDD) is a patient-reported outcome measure designed to assess the severity of core symptoms in clinical trials. preliminary version CSDD was developed based on regulatory guidance and hallmark identified by CDC. This study aimed evaluate content validity, determine whether it fit for purpose supporting efficacy endpoints trials treatments COVID-19. research also sought appropriateness newly Pre-COVID-19 Questionnaire. A targeted literature review completed...

10.2147/prom.s488914 article EN cc-by-nc Patient Related Outcome Measures 2025-01-01

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to its receptors, TRAIL-receptor 1 (TRAIL-R1) and 2 (TRAIL-R2), leading apoptosis by activation of caspase-8 the downstream executioner caspases, caspase-3 caspase-7 (caspase-3/7). Triple-negative breast cancer (TNBC) cell lines with a mesenchymal phenotype are sensitive TRAIL, whereas other resistant. The underlying mechanisms that control TRAIL sensitivity in cells not well understood. Here, we performed small...

10.1186/bcr3645 article EN cc-by Breast Cancer Research 2014-04-01

Fed human male subjects 18 to 30 years of age received 0.85 g/kg ethanol p.o. as vodka followed by a second drink (0.3-0.4 g/kg) given 3 4 hr later. Blood levels reached approximately 100 mg% after both doses. Breath samples were taken every 20 min, and the rate elimination was determined. Subjects returned 1 2 weeks later study repeated with fructose (1.0 g/kg). When simultaneously, peak blood values reduced significantly. This resulted in calculated increases apparent volume distribution...

10.1016/s0022-3565(25)38987-1 article EN Journal of Pharmacology and Experimental Therapeutics 1986-03-01

Patient-reported outcomes can measure health aspects that are meaningful to patients, such as 'life engagement' in major depressive disorder (MDD). Expert psychiatrists recently identified ten items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR) be used patient life engagement. This study aimed explore concept engagement and provide support for IDS-SR10 Life Engagement subscale perspective.Semi-structured video interviews were conducted with adults MDD United States....

10.1186/s41687-022-00517-z article EN cc-by Journal of Patient-Reported Outcomes 2022-10-12

The Atopic Dermatitis Control Tool (ADCT) assesses six concepts regarding patient-perceived control of atopic dermatitis (AD) in adults and adolescents with AD. This study aimed to develop two modified ADCT versions, one for children AD aged 8–11 years another caregivers 6 months 11 years. Following the US Food Drug Administration patient-reported outcomes guidance, was produce draft Child Caregiver maintaining original concepts. instruments were refined finalized through an iterative...

10.1007/s13555-024-01289-8 article EN cc-by-nc Dermatology and Therapy 2024-11-21

Abstract TNF-related apoptosis inducing ligand (TRAIL) selectively induces in transformed cells by activating the extrinsic apoptotic pathway via its cognate receptors on cell surface, TRAIL receptor 1 and 2. Triple negative breast cancer (TNBC) (so-called because TNBC lacks estrogen progesterone expression Her-2 amplification) have been found to be sensitive while of other subtypes disease remain relatively resistant. Unfortunately, mechanisms that govern sensitivity are not yet understood....

10.1158/1538-7445.am2015-15 article EN Cancer Research 2015-08-01

While patient-reported outcome measures are available to evaluate health-related quality of life and functioning in obesity, existing do not the impact excess weight loss on ability perform regularly occurring daily activities. Three iterative sets qualitative interviews were conducted two countries (United States, n = 23; United Kingdom, 23) with individuals body mass index ≥30 kg/m2 inform development Impact Weight Daily Activities Questionnaire (IWDAQ) for use clinical trials activity...

10.1111/cob.12387 article EN cc-by-nc-nd Clinical Obesity 2020-09-15

Abstract Background: Tumor Necrosis Factor Related Ligand (TRAIL) triggers apoptosis by binding to cell surface receptors. We previously showed that TRAIL receptor agonists preferentially kill TNBC cells with mesenchymal features (Basal B lines) through activation of Receptor 2 (TRAIL-R2). used preclinical models identify predictive biomarkers sensitivity and tested expression these markers in patient (pt) samples. Methods: the TRAIL-R2 specific agonist drozitumab vitro using viability...

10.1158/1538-7445.sabcs14-p5-10-05 article EN Cancer Research 2015-05-01

Abstract TNF-related apoptosis inducing ligand (TRAIL) is a member of the tumor necrosis factor super family and can induce apoptotic cell death upon binding to its cognate receptors, TRAIL Receptor 1 (TRAIL-R1) 2 (TRAIL-R2). has been found selectively in triple negative breast cancer (TNBC) lines (so called because cells lack estrogen progesterone receptor expression Her-2 amplification). Other subtypes are relatively resistant TRAIL-induced apoptosis. However, mechanisms that underlie...

10.1158/1538-7445.am2014-5124 article EN Cancer Research 2014-10-01
Coming Soon ...